Fed. Circ. Partially Revives AstraZeneca Asthma Drug IP Row

Law360, Los Angeles (October 30, 2013, 4:08 PM EDT) -- The Federal Circuit on Wednesday reversed a lower court’s non-infringement ruling on one patent in an intellectual property dispute over AstraZeneca PLC’s Pulmicort Respules pediatric asthma medication but upheld the court’s finding of obviousness on a second patent, among other issues.

The decision comes after AstraZeneca asked the appeals court in August to block four generic-drug makers from launching no-name versions of the pediatric asthma medication, which uses a nebulizer and is directed for use with children, saying the lower court relied too heavily on expert...
To view the full article, register now.